[go: up one dir, main page]

WO2008142319A3 - Peptide analogues of melanocortin receptors - Google Patents

Peptide analogues of melanocortin receptors Download PDF

Info

Publication number
WO2008142319A3
WO2008142319A3 PCT/FR2008/050588 FR2008050588W WO2008142319A3 WO 2008142319 A3 WO2008142319 A3 WO 2008142319A3 FR 2008050588 W FR2008050588 W FR 2008050588W WO 2008142319 A3 WO2008142319 A3 WO 2008142319A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide analogues
melanocortin receptors
receptors
melanocortin
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/050588
Other languages
French (fr)
Other versions
WO2008142319A2 (en
Inventor
Christel Gros
Roger Lahana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neorphys
Original Assignee
Neorphys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorphys filed Critical Neorphys
Publication of WO2008142319A2 publication Critical patent/WO2008142319A2/en
Publication of WO2008142319A3 publication Critical patent/WO2008142319A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present application relates to novel cyclic peptide analogues which have a good affinity for certain melanocortin receptor subtypes, specifically MC-4 receptors. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the treatment of conditions and diseases in which one or more melanocortin receptors are involved.
PCT/FR2008/050588 2007-04-04 2008-04-03 Peptide analogues of melanocortin receptors Ceased WO2008142319A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0754279 2007-04-04
FR0754279A FR2914646A1 (en) 2007-04-04 2007-04-04 PEPTIDE ANALOGUES OF MELANOCORTIN RECEPTORS

Publications (2)

Publication Number Publication Date
WO2008142319A2 WO2008142319A2 (en) 2008-11-27
WO2008142319A3 true WO2008142319A3 (en) 2009-02-19

Family

ID=38512128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/050588 Ceased WO2008142319A2 (en) 2007-04-04 2008-04-03 Peptide analogues of melanocortin receptors

Country Status (2)

Country Link
FR (1) FR2914646A1 (en)
WO (1) WO2008142319A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012990A (en) * 2008-05-27 2011-05-25 Genzyme Corp Peptide analogs of alpha-melanocyte stimulating hormone.
KR101687037B1 (en) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EP4100042A4 (en) * 2020-02-03 2024-04-10 Palatin Technologies, Inc. REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEDNAREK M A ET AL.: "Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, no. 3, 24 August 2001 (2001-08-24), pages 641 - 645, XP002396283, ISSN: 0006-291X *
BODI, J ET AL.: "Synthesis, biological activity and conformational investigations of novel cyclic melanotropin fragment analogs", PEPTIDES 1994, 23RD PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, BRAGA, PORTUGAL, 4 September 1994 (1994-09-04) - 10 September 1994 (1994-09-10), Editor: Maia, Hernani L.S.; Publisher: ESCOM, Leiden, Neth.; CODEN: 63MBAO, pages 611 - 612, XP009089973 *
DESAI P ET AL.: "Activity and conformation of a cyclic heptapeptide possessing the message sequence His-Phe-Arg-Trp of alpha-melanotropin", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 30, no. 3-4, 18 June 2002 (2002-06-18), Netherlands, pages 187 - 195, XP009089883, ISSN: 0141-8130 *
TSUDA Y ET AL.: "Synthesis of cyclic peptides with agonist activity for melanocortin receptors", PEPTIDE SCIENCE, no. 40, 29 October 2003 (2003-10-29), PROTEIN RESEARCH FOUNDATION, MINOO, JP, pages 227 - 230, XP009089900, ISSN: 1344-7661 *
VERTES A ET AL.: "Matrix-assisted laser desorption of peptides in transmission geometry", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 4, no. 7, 1990, HEYDEN, LONDON, GB, pages 263 - 266, XP009089984, ISSN: 0951-4198 *
XI NING: "The MC4 receptor as a drug discovery target", DRUGS OF THE FUTURE, vol. 31, no. 2, February 2006 (2006-02-01), pages 163 - 173, XP009090092, ISSN: 0377-8282 *
YING J ET AL.: "Solution structures of cyclic melanocortin agonists and antagonists by NMR.", BIOPOLYMERS, vol. 71, no. 6, 2003, pages 696 - 716, XP009090061, ISSN: 0006-3525 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9580466B2 (en) 2009-11-23 2017-02-28 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Also Published As

Publication number Publication date
FR2914646A1 (en) 2008-10-10
WO2008142319A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
IL194638A0 (en) Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
WO2010085700A3 (en) Treatment for obesity
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
BR112012017054A2 (en) "oxintomodulin peptide analog, its use as well as pharmaceutical composition"
IL209867A (en) Cyclic peptides, pharmaceutical compositions comprising them and uses thereof as medicaments
JO2645B1 (en) Compounds
UA86622C2 (en) Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine
WO2008142319A3 (en) Peptide analogues of melanocortin receptors
ATE542795T1 (en) BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS
TN2009000447A1 (en) An extented-release composition comprising a somatostatin derivative in microparticles
CL2007002643A1 (en) COMPOUNDS DERIVED FROM 5-PHENYL-NICOTINAMIDE, CB1 RECEIVER MODULATORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF NUTRITION DISORDERS, TYPE II DIABETES AND DEPENDENCE OF SUSTAN
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
PT1988914E (en) Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EA200802104A1 (en) APPLICATION OF COMPOSITIONS CONTAINING ANTAGONISTS OF CAPPA-OPIOID RECEPTORS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
PT1768985E (en) Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors
DE602007007934D1 (en) Imidazoazephinonverbindungen
IL188848A (en) Transient receptor potential type i (trpvi )antagonist, pharmaceutical composition containing it for the treatment of diseases and associated conditions
HUP0700782A3 (en) Novel peptides and amino acid derivatives, pharmaceutical compositions containing the same and use of the compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788112

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788112

Country of ref document: EP

Kind code of ref document: A2